Overview of Treatment of Hepatitis B: Key Approaches and Clinical Challenges

The development of nucleoside analogues has been a major advance in the treatment of hepatitis B; however, prolonged monotherapy is associated with drug resistance. Currently, no data in humans indicate that a combination of nucleoside analogues leads to enhanced efficacy. New nucleoside analogues with greater inhibitory effects on hepatitis B virus (HBV) replication being developed could prove to be more effective or less likely to be associated with viral resistance. Interferon still has a role to play in the management of chronic HBV infection. Recent data indicate that the response to interferon may be determined in part by differences in genotype. From a theoretical perspective, a combination of pegylated interferon with one or more nucleosides could induce a higher rate of virological response. Additional studies are needed to further address these issues.

KEYWORDS

Hepatitis B - nucleoside analogues - interferon - antiviral therapy

REFERENCES

• 1 Perrillo R P. Hepatitis B: treatment strategies for currently available drugs.  Curr. Hep. Reports. 2003;  2 63-70
• 2 Liaw Y F, Leung N, Guan R, Lau G KK, Merican I. Asian-Pacific consensus statement on the management of chronic hepatitis B: an update.  J Gastroenterol Hepatol. 2003;  18 239-245
• 3 Lok A SF, McMahon B J. AASLD practice guidelines. Chronic hepatitis B.  Hepatology. 2001;  34 1225-1241
• 4 EASL International Consensus Conference on Hepatitis B . 13-14 September, 2002: Geneva, Switzerland. Consensus statement (short version).  J Hepatol. 2003;  38 533-540 , (review)
• 5 Perrillo R, Schiff E, Yoshida E et al.. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants.  Hepatology. 2000;  32 129-134
• 6 Chang T-T, Hadziyannis S, Cianciara J et al.. Sustained viral load and ALT reduction following 48 weeks of entecavir treatment in subjects with chronic hepatitis B who have failed lamivudine.  Hepatology. 2002;  36 300A , (Abst)
• 7 van Bommel F, Wunsche T, Schurmann D et al.. A comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus (HBV) infection.  Hepatology. 2003;  38 275A , (Abst)
• 8 Perrillo R, Tamburro C, Regenstein F et al.. Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus.  Gastroenterology. 1995;  109 908-916
• 9 Nair S, Perrillo R P. Hepatitis B and D. In: Zakim D, Boyer T Hepatology: A Textbook of Liver Disease. Philadelphia; Saunders 2003: 959-1016
• 10 Perrillo R. Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease.  Gastroenterology. 2001;  120 1009-1022
• 11 Honkoop P, de Man R A, Niesters H G et al.. Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy.  Hepatology. 2000;  32 635-639
• 12 Wright T L. Clinical trial results and treatment resistance with lamivudine in hepatitis B.  Semin Liver Dis. 2004;  24(suppl 1) 31-36
• 13 Locarnini S A. Molecular virology of hepatitis B.  Semin Liver Dis. 2004;  24(suppl 1) 3-10
• 14 Dienstag J L, Goldin R D, Heathcote E J et al.. Histological outcome during long-term lamivudine therapy.  Gastroenterology. 2003;  124 105-117
• 15 Mutimer D, Pillay D, Shields P et al.. Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient.  Gut. 2000;  46 107-113
• 16 Perrillo R, Hann H W, Mutimer D et al.. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis virus.  Gastroenterology. 2004;  126 81-90
• 17 Peters M G, Hann H W, Heathcote E et al.. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant hepatitis B.  Gastroenterology. 2004;  126 91-101
• 18 Angus P, Vaughan R, Xiong S et al.. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase.  Gastroenterology. 2003;  125 292-297
• 19 Colonno R J, Weinheimer S, Rose R et al.. Emerging amino acid substitutions in lamivudine-resistant HBV that result in reduced susceptibility to entecavir. Presented at the 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy September 14-17, 2003 Chicago, IL;
• 20 Lai C-L, Leung N WY, Teo E-T et al.. Results of a one-year international phase IIB comparative trial of telbivudine, lamivudine, and the combination in patients with chronic hepatitis B.  Hepatology. 2003;  38 262A , (Abst)
• 21 Sung J JY, Lai J Y, Zeuzem S et al.. A randomized double-blind phase II study of lamivudine compared to lamivudine plus adefovir dipivoxil for treatment naïve patients with chronic hepatitis B: week 52 analysis.  J Hepatol. 2003;  38 25-26 , (Abst)
• 22 Wong D K, Cheung A M, O'Rourke K et al.. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis.  Ann Intern Med. 1993;  119 312-323
• 23 Nair S, Perrillo R. Serum alanine aminotransferase flares during interferon treatment of chronic hepatitis B: is sustained clearance of HBV DNA dependent on levels of pretreatment viremia?.  Hepatology. 2001;  34 1021-1026
• 24 Cooksley W GE, Piratvisuth T, Lee S-D et al.. Peginterferon alfa-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B.  J Viral Hepat. 2003;  10 298-305
• 25 Cooksley W G. Treatment with interferons in patients with hepatitis B.  Semin Liver Dis. 2004;  24(suppl 1) 45-54
• 26 Marcellin P, Lau G KK, Bonino F et al.. A phase II, partially double-blinded study evaluating the efficacy and safety of peginterferon alfa-2° (40KD) (Pegasys^®) alone or in combination with lamivudine vs lamivudine in 537 patients with HBeAg-negative/anti-HBe-positive chronic hepatitis B.  Hepatology. 2003;  38 724A , (Abst)
• 27 Hansen H LA, Senturk H, Zeuzem S et al.. Peginterferon alfa-2b and lamivudine combination therapy compared with peginterferon alfa-2b for chronic HBeAg positive chronic hepatitis B: a randomized controlled trial in 307 patients. Presented at the 54th Annual Meeting of the American Association for the Study of Liver Diseases October 28, 2003 Boston, MA;
• 28 Westland C, Delaney IV W, Yang H et al.. Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil.  Gastroenterology. 2003;  125 107-116
• 29 Kao J H, Wu N H, Chen P J et al.. Hepatitis B genotypes and the response to interferon therapy.  J Hepatol. 2000;  33 998-1002
• 30 Chu C-J, Keeffe E B, Han S-H et al.. Hepatitis B virus genotypes in the United States: results of a nationwide study.  Gastroenterology. 2003;  125 444-451
• 31 Korba B E, Cote P, Hornbuckle W et al.. Enhanced antiviral benefit of combination therapy with lamivudine and alpha interferono against WHV replication in chronic carrier woodchucks.  Antivir Ther. 2000;  5 95-104
• 32 Schalm S W, Heathcote J, Cianciara J et al.. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomized trial.  Gut. 2000;  46 562-568
• 33 Santantonio T, Niro G A, Sinisi E et al.. Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B patients: a controlled pilot study.  J Hepatol. 2003;  36 799-804
• 34 Samuel D. Management of Hepatitis B in liver transplantation patients.  Semin Liver Dis. 2004;  24(suppl 1) 55-62